RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Peking University Cancer Hospital, National Cancer Center Hospital, Asan Medical Center, University of Ulsan, The University of Texas MD Anderson Cancer Center, Fudan University Shanghai Cancer Center, Fujian Medical University, Fujian Provincial Cancer Hospital, Zhejiang Cancer Hospital, Jiangsu Province Hospital, First Affiliated Hospital of Xiamen University, Zhengzhou University, Henan Cancer Hospital, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Shandong Tumor Hospital, Shandong First Medical University, Samsung Medical Center, China Medical University, China Medical University Hospital, Saitama Cancer Center, Hospital Universitario Miguel Servet, Centre Hospitalier Universitaire de Besançon, BeiGene (China), KU Leuven
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3172772308